Literature DB >> 23959540

PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.

Snehal Dabir1, Amy Kluge, Karen McColl, Yu Liu, Minh Lam, Balazs Halmos, Gary Wildey, Afshin Dowlati.   

Abstract

Protein inhibitor of activated signal transducer and activator of transcription 3 (STAT3) (PIAS3) is an endogenous inhibitor of STAT3 that negatively regulates STAT3 transcriptional activity and cell growth and demonstrates limited expression in the majority of human squamous cell carcinomas of the lung. In this study, we sought to determine whether PIAS3 inhibits cell growth in non-small cell lung cancer cell lines by inducing apoptosis. Our results demonstrate that overexpression of PIAS3 promotes mitochondrial depolarization, leading to cytochrome c release, caspase 9 and 3 activation and poly (ADP-ribose) polymerase cleavage. This intrinsic pathway activation was associated with decreased Bcl-xL expression and increased Noxa expression and was independent of p53 status. Furthermore, PIAS3 inhibition of STAT3 activity was also p53 independent. Microarray experiments were performed to discover STAT3-independent mediators of PIAS3-induced apoptosis by comparing the apoptotic gene expression signature induced by PIAS3 overexpression with that induced by STAT3 siRNA. The results showed that a subset of apoptotic genes was uniquely expressed only after PIAS3 expression. Thus, PIAS3 may represent a promising lung cancer therapeutic target because of its p53-independent efficacy and its potential to synergize with Bcl-2 targeted inhibitors.
© 2013 UICC.

Entities:  

Keywords:  Noxa; PIAS3; STAT3; apoptosis; lung cancer; p53

Mesh:

Substances:

Year:  2013        PMID: 23959540      PMCID: PMC4199747          DOI: 10.1002/ijc.28448

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

1.  Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.

Authors:  Eric B Haura; Zhong Zheng; Lanxi Song; Alan Cantor; Gerold Bepler
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.

Authors:  Paula Hauck; Bo H Chao; Julie Litz; Geoffrey W Krystal
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

3.  A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells.

Authors:  James Turkson; Shumin Zhang; Linda B Mora; Audrey Burns; Said Sebti; Richard Jove
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

4.  Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.

Authors:  Tania Cortas; Rosana Eisenberg; Pingfu Fu; Jeffrey Kern; Lauren Patrick; Afshin Dowlati
Journal:  Lung Cancer       Date:  2006-12-08       Impact factor: 5.705

5.  Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells.

Authors:  Mehmet Kemal Tur; Inga Neef; Edgar Jost; Oliver Galm; Gernot Jäger; Michael Stöcker; Markus Ribbert; Rainhardt Osieka; Uwe Klinge; Stefan Barth
Journal:  J Immunother       Date:  2009-06       Impact factor: 4.456

6.  Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression.

Authors:  Emily C Brantley; L Burton Nabors; G Yancey Gillespie; Youn-Hee Choi; Cheryl Ann Palmer; Keith Harrison; Kevin Roarty; Etty N Benveniste
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

7.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

Authors:  Sizhi Paul Gao; Kevin G Mark; Kenneth Leslie; William Pao; Noriko Motoi; William L Gerald; William D Travis; William Bornmann; Darren Veach; Bayard Clarkson; Jacqueline F Bromberg
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 8.  Noxa: at the tip of the balance between life and death.

Authors:  C Ploner; R Kofler; A Villunger
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

9.  SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.

Authors:  Afshin Dowlati; Amy Kluge; David Nethery; Balazs Halmos; Jeffrey A Kern
Journal:  Anticancer Drugs       Date:  2008-01       Impact factor: 2.248

Review 10.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.

Authors:  M Vogler; D Dinsdale; M J S Dyer; G M Cohen
Journal:  Cell Death Differ       Date:  2008-09-19       Impact factor: 15.828

View more
  6 in total

1.  PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.

Authors:  Ester Bonastre; Sara Verdura; Ilse Zondervan; Federica Facchinetti; Sylvie Lantuejoul; Maria Dolores Chiara; Juan Pablo Rodrigo; Julian Carretero; Enric Condom; Agustin Vidal; David Sidransky; Alberto Villanueva; Luca Roz; Elisabeth Brambilla; Suvi Savola; Montse Sanchez-Cespedes
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

2.  Two serine residues of non-metastasis protein 23-H1 are critical in inhibiting signal transducer and activator of transcription 3 activity in human lung cancer cells.

Authors:  Zhihao Wu; Lili Guo; Jiangnan Ge; Zhijian Zhang; Huijun Wei; Qinghua Zhou
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

3.  PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.

Authors:  Liyan Chen; Tiefeng Jin; Kun Zhu; Yingshi Piao; Taihao Quan; Chunji Quan; Zhenhua Lin
Journal:  Oncotarget       Date:  2017-02-14

4.  PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.

Authors:  Rime Abbas; Karen S McColl; Adam Kresak; Michael Yang; Yanwen Chen; Pingfu Fu; Gary Wildey; Afshin Dowlati
Journal:  Cancer Med       Date:  2015-01-09       Impact factor: 4.711

5.  Identification of druggable cancer driver genes amplified across TCGA datasets.

Authors:  Ying Chen; Jeremy McGee; Xianming Chen; Thompson N Doman; Xueqian Gong; Youyan Zhang; Nicole Hamm; Xiwen Ma; Richard E Higgs; Shripad V Bhagwat; Sean Buchanan; Sheng-Bin Peng; Kirk A Staschke; Vipin Yadav; Yong Yue; Hosein Kouros-Mehr
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240

Review 6.  Multiple regulation pathways and pivotal biological functions of STAT3 in cancer.

Authors:  Jie Yuan; Fei Zhang; Ruifang Niu
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.